PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial

PDF) Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular AMD Patients: A “Real World” Analysis in 49,485 Eyes

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study, BMC Ophthalmology

A prospective, observational, open‐label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age ‐related macular degeneration - Asten - 2015 - Acta Ophthalmologica - Wiley Online Library

Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records - ScienceDirect

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration

Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study

Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan – Results from the 12-month, observational RENOWNED study - ScienceDirect

Biomolecules, Free Full-Text

The management of neovascular age‐related macular degeneration: A systematic literature review of patient‐reported outcomes, patient mental health and caregiver burden - Gale - 2023 - Acta Ophthalmologica - Wiley Online Library

Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study, BMC Ophthalmology

PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records - ScienceDirect